On 2 May 2024, Novo Nordisk A/S will announce financial results for the three first months of 2024.
An earnings call will follow the announcement at:
13.00-14.00 (CEST)
12.00-13.00 (BST)
07.00-08.00 (EDT)
https://edge.media-server.com/mmc/p/ywqntbg4
To access the earnings call, please register at the following link to ask questions: https://register.vevent.com/register/BI1086a4b1e546428a82d4f9ce7d81a00d
Novo Nordisk A/S will host a London conference call on 3
May 2024 in relation to Q1 2024 results announced on 2 May
2024.
The London conference call will be at:
14.15-15.30 (CEST)
13.15-14.30 (BST)
8.15-9.30 (EDT)
Novo Nordisk A/S announced financial results for the full year of 2023:
Novo Nordisk A/S hosted a R&D investor call in relation to the
annual American Heart Association (AHA) conference. This year the
conference is hosted in in Philadelphia, US.
Novo Nordisk A/S hosted a R&D investor call in relation to the annual ADA conference. This year the conference is hosted in San Diego, CA.
Full-year 2022 financial results were published 01 February 2023, 7:30 CET:
The conference call took place 01 February 2023,
13:00 CET
In connection with ADA 82nd Scientific Sessions Novo Nordisk A/S will host an investor event.